Advanced search
Start date
Betweenand
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

Activity of paromomycin against Leishmania amazonensis: Direct correlation between susceptibility in vitro and the treatment outcome in vivo

Full text
Author(s):
Coser, Elizabeth M. [1] ; Ferreira, Bianca A. [1] ; Branco, Nilson [1] ; Yamashiro-Kanashiro, Edite H. [2, 3] ; Lindoso, Jose Angelo L. [4, 5] ; Coelho, Adriano C. [1]
Total Authors: 6
Affiliation:
[1] Univ Estadual Campinas, Inst Biol, Dept Biol Anim, UNICAMP, Campinas - Brazil
[2] Univ Sao Paulo, Fac Med, Inst Med Trop Sao Paulo, Lab Soroepidemiol & Imunobiol, Sao Paulo - Brazil
[3] Univ Sao Paulo, Fac Med, Dept Molestias Infecciosas & Parasitarias, Lab Imunol LIM 48, Sao Paulo - Brazil
[4] Inst Infectol Emilio Ribas, Sao Paulo - Brazil
[5] Univ Sao Paulo, Fac Med, Inst Med Trop Sao Paulo, Lab Protozool, Dept Molestias Infecciosas & Parasi, Sao Paulo - Brazil
Total Affiliations: 5
Document type: Journal article
Source: INTERNATIONAL JOURNAL FOR PARASITOLOGY-DRUGS AND DRUG RESISTANCE; v. 14, p. 91-98, DEC 2020.
Web of Science Citations: 1
Abstract

Paromomycin is an aminoglycoside antibiotic approved in 2006 for the treatment of visceral leishmaniasis caused by Leishmania donovani in Southeast Asia. Although this drug is not approved for the treatment of visceral and cutaneous leishmaniasis in Brazil, it is urgent and necessary to evaluate the potential of this drug as alternative for the treatment against species responsible for these clinical forms of the disease. In Brazil, Leishmania amazonensis is responsible for cutaneous and diffuse cutaneous leishmaniasis. The diffuse cutaneous form of the disease is difficult to treat and frequent relapses are reported, mainly when the treatment is interrupted. Here, we evaluated paromomycin susceptibility in vitro of a L. amazonensis clinical isolate from a patient with cutaneous leishmaniasis and the reference strain L. amazonensis M2269, as well as its in vivo efficacy in a murine experimental model. Although never exposed to pammomycin, a significant differential susceptibility between these two lines was found. Paromomycin was highly active in vitro against the clinical isolate in both forms of the parasite, while its activity against the reference strain was less active. In vivo studies in mice infected with each one of these lines demonstrated that paromomycin reduces lesion size and parasite burden and a direct correlation between the susceptibility in vitro and the effectiveness of this drug in vivo was found. Our findings indicate that paromomycin efficacy in vivo is dependent on intrinsic susceptibility of the parasite. Beyond that, this study contributes for the evaluation of the potential use of paromomycin in chemotherapy of cutaneous leishmaniasis in Brazil caused by L. amazonensis. (AU)

FAPESP's process: 16/21171-6 - Paromomycin for the treatment of Tegumentary Leishmaniasis: investigation in vitro, in vivo and in the identification of molecular markers associated with susceptibility and resistance
Grantee:Adriano Cappellazzo Coelho
Support type: Research Grants - Young Investigators Grants
FAPESP's process: 18/03299-0 - Evaluation of the efficacy of paromomycin in the treatment of experimental cutaneous leishmaniasis
Grantee:Elizabeth Magiolo Coser
Support type: Scholarships in Brazil - Master
FAPESP's process: 20/01948-1 - Evaluation of susceptibility in vitro of clinical and dog isolates of Leishmania spp. to alternative drugs
Grantee:Bianca Alves Ferreira
Support type: Scholarships in Brazil - Master